Crestor and Bladder transitional cell carcinoma - a phase IV clinical study of FDA data

Summary:

Bladder transitional cell carcinoma is reported as a side effect among people who take Crestor (rosuvastatin calcium), especially for people who are male, 60+ old, have been taking the drug for 6 - 12 months also take Actos, and have Type 2 diabetes.

The phase IV clinical study analyzes which people have Bladder transitional cell carcinoma when taking Crestor. It is created by eHealthMe based on reports of 143,349 people who have side effects when taking Crestor from the FDA, and is updated regularly.

What is Crestor?

Crestor has active ingredients of rosuvastatin calcium. It is often used in high blood cholesterol. eHealthMe is studying from 149,761 Crestor users. Check the latest studies of Crestor.

What is Bladder transitional cell carcinoma?

Bladder transitional cell carcinoma (types of bladder cancer) is found to be associated with 203 drugs and 229 conditions by eHealthMe. Check the latest studies of Bladder transitional cell carcinoma.

On Jul, 10, 2026

143,349 people reported to have side effects when taking Crestor.
Among them, 25 people (0.02%) have Bladder transitional cell carcinoma.

Could Crestor cause Bladder transitional cell carcinoma?

Among these 25 people:

How long have people been on Crestor when they have Bladder transitional cell carcinoma? *

What is the gender of people who have Bladder transitional cell carcinoma when taking Crestor? *

female: 12.5 %
male: 87.5 %

What is the age of people who have Bladder transitional cell carcinoma when taking Crestor? *

What are other drugs people take besides Crestor? *

What are other side effects people have besides Bladder transitional cell carcinoma? *

Haematuria (presence of blood in urine): 5 people, 20.00%
Kidney Stones: 3 people, 12.00%
Enlarged Prostate: 3 people, 12.00%
Escherichia Urinary Tract Infection (urinary tract infection by escherichia coli): 2 people, 8.00%
Prostate Cancer: 2 people, 8.00%
Stress And Anxiety: 2 people, 8.00%
Neuropathy Peripheral (surface nerve damage): 2 people, 8.00%
Weight Loss: 1 person, 4.00%
Diabetic Nephropathy (diabetic kidney disease): 1 person, 4.00%
Diabetic Neuropathy (neuropathic disorders that are associated with diabetes mellitus): 1 person, 4.00%

What are the existing conditions these people have? *

Type 2 Diabetes: 13 people, 52.00%
Diabetes: 5 people, 20.00%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 3 people, 12.00%
Multiple Myeloma (cancer of the plasma cells): 3 people, 12.00%
High Blood Pressure: 3 people, 12.00%
Bone Disorder: 2 people, 8.00%
Constipation: 2 people, 8.00%
Whipple's Disease (infection with a bacteria called tropheryma whippelii): 1 person, 4.00%
Glaucoma (increased fluid pressure in the eye with vision loss): 1 person, 4.00%
Anaemia (lack of blood): 1 person, 4.00%

* Approximation only. Some reports may have incomplete information.

Do you take Crestor and have Bladder transitional cell carcinoma?

- Check whether Bladder transitional cell carcinoma is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Crestor:

Crestor (149,761 reports)

Browse all side effects of Crestor:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Bladder transitional cell carcinoma:

Bladder transitional cell carcinoma (203 drugs)

Browse all the conditions that are associated with Bladder transitional cell carcinoma:

Bladder transitional cell carcinoma (229 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on rosuvastatin calcium (the active ingredients of Crestor) and Crestor (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.